DIABETES Add-on to metformin in T2DM-linagliptin or glimepiride?

被引：2
|
作者：
Christensen, Mikkel [2 ]
Knop, Filip K. [1 ]
机构：
[1] Univ Copenhagen, Diabet Res Div, Dept Internal Med, Gentofte Hosp, DK-2900 Hellerup, Denmark
[2] Univ Copenhagen, Bispebjerg Hosp, Dept Clin Pharmacol, DK-2400 Copenhagen, Denmark
来源：
NATURE REVIEWS ENDOCRINOLOGY | 2012年 / 8卷 / 10期
关键词：
HYPOGLYCEMIA; ASSOCIATION;
D O I：
10.1038/nrendo.2012.163
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Clinicians are responsible for selecting a suitable second-line treatment for patients with type 2 diabetes mellitus when metformin monotherapy fails. New evidence could aid clinicians in deciding between one of the most commonly used second-line agents, glimepiride, and the recently approved dipeptidyl peptidase 4 inhibitor linagliptin.
引用
收藏
页码：576 / 578
页数：3
相关论文
共 50 条
  • [41] Time To Add-On Medication Use for Patients with Type 2 Diabetes Mellitus (T2DM) Who Failed Metformin Monotherapy
    Qiu, Ying
    Fu, Alex Z.
    Radican, Larry
    DIABETES, 2010, 59 : A70 - +
  • [42] TIME TO ADD-ON MEDICATION USE FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) WHO FAILED METFORMIN MONOTHERAPY
    Qiu, Y.
    Fu, A. Z.
    Radican, L.
    VALUE IN HEALTH, 2010, 13 (07) : A299 - A299
  • [43] Empagliflozin (EMPA) as add-on to linagliptin (LINA) and metformin in patients with type 2 diabetes (T2DM): a 24-week randomised, double-blind, parallel-group trial
    Maldonado-Lutomirsky, M.
    Softeland, E.
    Meier, J. J.
    Vangen, B.
    Toorawa, R.
    Woerle, H. -J.
    Broedl, U. C.
    DIABETOLOGIA, 2016, 59 : S93 - S93
  • [44] Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece
    Hara Kousoulakou
    Magdalini Hatzikou
    Varvara Baroutsou
    John Yfantopoulos
    Cost Effectiveness and Resource Allocation, 15
  • [45] Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece
    Kousoulakou, Hara
    Hatzikou, Magdalini
    Baroutsou, Varvara
    Yfantopoulos, John
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2017, 15
  • [46] Liraglutide significantly improves glycemic control and reduces body weight compared with glimepiride as add-on to metformin in type 2 diabetes
    Nauck, MA
    Hompesch, M
    Filipczak, R
    Le, TDT
    Nielsen, L
    Zdravkovic, M
    Gumprecht, J
    DIABETES, 2004, 53 : A83 - A83
  • [47] Effect of empagliflozin compared with glimepiride as add-on to metformin for 2 years on the amount and distribution of body fat in patients with type 2 diabetes
    Kim, G.
    Ridderstrale, M.
    Andersen, K. R.
    Zeller, C.
    Woerle, H. J.
    Broedl, U. C.
    DIABETOLOGIA, 2014, 57 : S330 - S331
  • [48] Liraglutide as add-on to metformin in type 2 diabetes: significant improvement in glycaemic control with a reduction in body weight compared with glimepiride
    Nauck, M
    Hompesch, N
    Filipczak, R
    Le, TTD
    Nielsen, L
    Zdravkovic, M
    Gumprecht, J
    DIABETOLOGIA, 2004, 47 : A281 - A281
  • [49] Economic Evaluation of Dapagliflozin as Add-On to Metformin in T2DM in the Israeli Health Care Setting
    Moshel, Shai
    Vexberg, Michal Hirsch
    Shavit, Oren
    Toledano, Yoel
    DIABETES, 2018, 67
  • [50] GlyCemic Control with Add-On Medication Use for Patients with Type 2 Diabetes Mellitus (T2DM) Who Failed Metformin Monotherapy
    Fu, Alex Z.
    Qiu, Ying
    Radican, Larry
    DIABETES, 2010, 59 : A612 - A613
12345